Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Kedor C, Specker C, Seipelt E, Schulze-Koops H, Rubbert-Roth A, Kekow J, Henes J, Blank N, Behrens F, Weiß A, Zernicke J, Listing J, Feist E. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020; 79:1090-1097.
13.05.2020
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
13.05.2020
Ann Rheum Dis 2020; 79:1090-1097
Kedor Claudia, Specker Christof, Seipelt Eva, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Kekow Joern, Henes Joerg Christoph, Blank Norbert, Behrens Frank, Weiß Anja, Zernicke Jan, Listing Joachim, Feist Eugen
Weiter